PIPE Transactions: Registered Direct, Structured PIPE, and Variants

Introduction

A PIPE (Private Investment in Public Equity) is the principal alternative to public follow-on offerings for situations where speed, discretion, and execution certainty matter more than maximizing the buyer base. The structure places equity (or equity-linked instruments) to a small group of pre-identified institutional investors through a private placement under Section 4(a)(2) or Reg D Rule 506, bypassing the public marketing process. PIPEs are fully agreed and signed before public announcement, eliminating busted-deal risk in stressed windows. The structure dominates among biotech and technology issuers: a clinical-stage biotech can sign a $75 million placement with five crossover funds in 10 days, where a marketed follow-on of the same size could break the stock and still fail to clear.

The traditional PIPE structure places newly issued common stock to a defined group of institutional investors at a negotiated discount to the prevailing market price.

The Investor Universe

PIPEs are restricted to accredited and institutional investors. Typical investor lists run 5 to 20 names (versus 50 to 150 for a public follow-on). Reg D Rule 506(b) limits the offering to accredited investors with disclosure protection; Rule 506(c) allows general solicitation but requires verified accreditation. Most PIPEs use 506(b) to maintain confidentiality during negotiation.

Pricing and Discount

PIPE shares are typically issued at a 2 to 10 percent discount to market depending on issuer size, situation, and placement size relative to ADV. Life sciences PIPEs in the first half of 2025 priced at an average 5.2 percent discount. The discount compensates for restricted-share illiquidity and supply absorption risk.

Resale Registration

PIPE shares are restricted at issuance and become tradable only after the issuer files a resale registration statement and it becomes effective. The issuer typically commits to file within 30 to 60 days of closing and to maintain effectiveness, with liquidated damages for late filing.

A registered direct offering (RDO) is a hybrid structure that combines elements of public and private placements: the offering is sold privately to a small group of institutional investors, but the shares are issued as freely-tradable registered shares (not restricted) because the issuer has an effective shelf registration covering the offering.

Registered Direct Offering (RDO)

A securities offering placed privately to a small group of institutional investors but issued as freely tradable registered shares (rather than restricted PIPE shares), typically using the issuer's existing shelf registration. RDOs combine the PIPE's confidential negotiation and execution speed with the better post-closing liquidity that registered shares provide. RDOs price at tighter discounts than equivalent traditional PIPEs (typically 2-5 percent versus 5-10 percent for PIPEs) but are constrained to issuers with effective shelf capacity and shareholder authorization for the placement.

RDO vs PIPE Trade-Off

The principal RDO advantage is freely tradable shares (no restricted-share illiquidity discount). Life sciences RDOs priced at a 2.4 percent average discount in H1 2025 versus 5.2 percent for PIPEs. RDOs are constrained to issuers with effective shelves and sufficient remaining capacity. Issuers without an effective shelf default to PIPEs, and some choose PIPEs even with shelf available to maintain stronger contractual protections (registration rights, transfer restrictions, anti-dilution covenants).

Beyond the common-stock PIPE, structured PIPEs use more complex instruments to deliver customized economics for both issuer and investor.

Convertible PIPE and Preferred PIPE

A convertible PIPE places convertible bonds or convertible preferred privately, combining the PIPE's privacy with the convertible's lower cost of capital. Common in biotech for clinical trial funding. A preferred PIPE places preferred stock (cumulative or non-cumulative, convertible or non-convertible) at a defined dividend rate, common in capital-heavy or rating-sensitive issuers where equity-credit treatment matters.

Warrants and Warrant Coverage

Many PIPEs (particularly in stressed or smaller-cap situations) include warrant coverage: each PIPE share comes with an attached warrant entitling the holder to buy additional shares at a defined exercise price for a defined period (typically 3 to 5 years). Warrant coverage compensates investors for the illiquidity and supply-absorption risk.

Warrant Coverage (PIPE Context)

A structuring feature in some PIPE transactions whereby each PIPE share is paired with an attached warrant entitling the holder to purchase additional shares at a defined exercise price for a defined period (typically 3 to 5 years). Warrant coverage is expressed as a percentage (a 25 percent warrant coverage means each share comes with a warrant for 0.25 additional shares). The feature compensates investors for the PIPE's illiquidity and supply-absorption risk and is a flexible structuring lever issuers and investors use to bridge price gaps in the negotiation.

Pre-Funded Warrants

Pre-funded warrants are a specialized PIPE structure where the warrant's exercise price is paid upfront at issuance (typically $0.0001 per share), with the warrant exercisable at the holder's option without additional payment. The structure functions economically as PIPE shares but with the technical legal classification of warrants, which can avoid certain ownership-percentage restrictions investors face under Section 13 reporting or fund concentration limits. Pre-funded warrants are common in biotech PIPEs where investor concentration limits would otherwise constrain participation size.

Variable-Reset Structured PIPEs

A more aggressive variant of structured PIPE includes a variable-reset conversion price that adjusts downward if the issuer's stock falls below defined thresholds. The structure (sometimes called "toxic" or "death-spiral" PIPEs) protects investors from price declines but creates progressive dilution for existing shareholders if the stock falls. Variable-reset structures are uncommon in healthy markets but appear in stressed-issuer situations where investors require strong downside protection in exchange for committing capital.

The PIPE versus public follow-on choice turns on speed, certainty, market window, and issuer profile.

Speed and Certainty

PIPEs and RDOs are fully negotiated before announcement, eliminating the busted-deal risk that public follow-ons carry. For issuers with binary catalysts (pending clinical trial data, M&A close deadlines) or in stressed market windows, the certainty of execution is often worth the somewhat wider discount typical of PIPEs.

Discretion

The PIPE structure lets the issuer raise capital without the public visibility of a follow-on launch. The discretion is valuable for issuers who do not want to signal capital constraints to competitors or customers, and for issuers in M&A processes where a public follow-on would interfere with deal negotiations.

Investor Customization and Documentation

PIPEs allow heavily customized terms (warrants, covenants, registration rights, board seats, anti-dilution adjustments) that public follow-ons cannot accommodate. PIPE documentation typically includes a Securities Purchase Agreement (SPA), a Registration Rights Agreement (resale registration filing within 30-45 days, effectiveness within 90-120 days), an investor questionnaire confirming accredited or QIB status, a legal opinion from issuer counsel, and (for convertible preferred PIPEs) a Certificate of Designations defining the preferred's rights, dividends, and conversion mechanics.

The Crossover Investor Universe

Biotech PIPEs are dominated by the crossover-investor universe: RA Capital, Perceptive Advisors, Baker Brothers, Deerfield Management, Foresite Capital, plus dedicated biotech teams at Fidelity, T. Rowe Price, and BlackRock. Generalist hedge funds (Viking, Citadel) and sovereign wealth funds (GIC, Temasek, Mubadala) have built dedicated life-sciences teams that participate alongside the specialists. The crossover universe typically commits $50 to $200 million per round at the late-stage private (Series C+) and post-IPO PIPE level, with the explicit thesis that the issuer will continue executing toward clinical milestones during the holding period.

The example above ends 45 days post-closing with effective resale registration, but the issuer's work does not end there: the day registration goes effective, the eight investors who funded the PIPE can begin selling, and the issuer's stock dynamic shifts in a predictable way.

Managing that post-effectiveness selling dynamic, and getting the right investors into the round in the first place, both come back to the bank's standing relationships with the small group of names that dominate PIPE allocations.

A small group of pre-identified investors, a confidential negotiation, a fully-signed deal before announcement, and customized terms public follow-ons cannot accommodate: that is what every PIPE comes down to, and why biotechs and stressed-window issuers reach for the structure ahead of public alternatives. So far this section has covered the convertible-bond product set; one more piece of plumbing supports almost every US convertible: the 144A private placement market that hosts the actual distribution. The 144A convertible offering is the section's final article.